Global Antivenom Industry Research Report, Growth Trends and Competitive Analysis 2021-2027

Report Description


The Global Antivenom Market Report provides Insightful information to the clients enhancing their basic leadership capacity identified with the global Antivenom Market business, including market dynamics, segmentation, competition, and regional growth. The strategy of expansion has been adopted by key players who are increasing their production capacities to cater to the increasing demand for various application.

New traders at intervals the Antivenom Market face strong competition from ancient world traders as they try with technological revolutions, dependableness and commonplace of Antivenom Market product affairs. The report is at risk of project regarding this Antivenom Market evolutions and additionally the magnitude of competition, value and extra.

Leading market players: (Option 1: Free 25% Customization Profiles of 5 Additional Companies of your Choice)


This business intelligence report offers profiling of reputed companies that are operating in the market. Companies such as:

  • CSL Behring
  • Merck & Co.
  • BTG Plc
  • Pfizer
  • Haffkine Bio-Pharmaceutical Corporation
  • Rare Disease Therapeutics
  • Flynn Pharma
  • Vins Bioproducts
  • Bharat Serums and Vaccines
  • Serum Biotech

Others players have been profiled into detail so as to offer a glimpse of the market leaders. Moreover, parameters such as Antivenom related investment & spending and developments by major players of the market are tracked in this Global report.

Years considered for the study:


Antivenom Market

Antivenom Market

Report Highlights:


The Antivenom Market is widely partitioned reliant on the predictable updates in the enhancement of parameters for example, quality, trustworthiness, end customer solicitations, applications, and others. The Antivenom Market report contains general successful parameters, confinements, and besides has in detail illumination of the noteworthy data close by the present and future examples that may concern the advancement. The comprehensive Antivenom Market report elucidates within and outside representation of current advancements, parameters, and establishments.

The key regions analyzed in this study include North America, Europe, Japan, China, India, Korea, South East Asia, South America, Middle East and African countries. The leading players of Antivenom Market and their geographical presence across the globe are estimated based on production capacity, utilization ratio, consumer base, demand and supply scenario, profit margin and Antivenom marketers.

Data Lab Forecast performed primary as well as exhaustive secondary research for this study. We conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, DLF was able to include manufacturers that could not be identified due to the limitations of secondary research. We analysed product offerings, distribution channel and regional presence of all major companies in the industry.

Data Lab Forecast calculated the market size for the Antivenom market using a bottom-up approach, wherein manufacturers value data for different type (Polyvalent antivenom, Monovalent antivenom), of Antivenom market was recorded as well as forecast for the future years was made. Data Lab Forecast sourced these values from industry experts and company representatives, and externally validated through analyzing historical sales data of respective manufacturers to arrive at the overall market size. Various secondary sources such as company annual reports, white papers, investor presentations and financial reports were also studied by Data Lab Forecast.

Antivenom Market

Antivenom Market

Key Target Audience:


  • Antivenom market companies.
  • Research organizations and consulting companies.
  • Organizations, associations and alliances related to the Antivenom market industry.
  • Government bodies such as regulating authorities and policymakers.
  • Industry associations.

The study is useful in providing answers to several critical questions that are important for industry stakeholders, such as manufacturers, distributors, dealers and policymakers, about which market segments should be targeted over retail cosmetics outlets in coming years to strategize investments and capitalize on growth of the market.

Report Scope:


In this report, Antivenom market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

In terms of type, the Global Antivenom market is segregated into:


The report includes in-detail references of all the notable product categories as well as application specifications. The product segment is described on the basis of key player development traits, sales overview, volume based returns and the like.

  • Polyvalent antivenom
  • Monovalent antivenom

By end-user also classify into, the Global Antivenom market:


Global Antivenom market also specifically underpins end-use application scope and their improvements based on technological developments and consumer preferences.

  • Retail Pharmacies
  • Hospitals
  • Others

Highlights of this 2021-2027 Antivenom Market Report:

  • Market dynamics, Antivenom economy manufacturing, opportunities on the total pricing of this top manufacturer and improvement trend analysis;
  • Antivenom industry players at the general regional industry and economy synopsis;
  • Deep analysis of the most significant market players included by Worldwide Antivenom Market study report;
  • Understand more about the market plans that are increasingly now being adopted by leading Antivenom businesses;
  • Evaluation of this market character, namely market development drivers, essential challengers, inhibitors, and chances;
  • Strategically profile the key players and comprehensively analyze their growth strategies.

Competitive Landscape:

Company Profiles: Detailed analysis of the major companies presents in the Antivenom market.

Product Benchmarking: Benchmarking of most selling variant of all leading companies based on product type. In-depth analysis of benchmarking and recommendation on ideal product specifications.

Voice of Customer: Customer analysis by considering the major factors influencing the purchasing decision.

Available Customizations:

With the given market data, Data Lab Forecast offers customizations according to the companys specific needs. The following customization options are available for the report:

Channel Partner Analysis: Detailed list of distributors and dealers across the country.

Company Information: Detailed analysis and profiling of additional market players (up to five).

Product Information: Detailed analysis of new products in the market and their driving forces in the market.

In case you dont find what you are looking for, please get in touch with our custom research team at sales@datalabforecast.com

TableofContents 1ReportOverview 1.1ResearchScope 1.2TopAntivenomManufacturersCovered:RankingbyRevenue 1.3MarketSegmentbyType 1.3.1GlobalAntivenomMarketSizebyType:2016VS2021VS2027(US$Million) 1.3.2Polyvalentantivenom 1.3.3Monovalentantivenom 1.4MarketSegmentbyApplication 1.4.1GlobalAntivenomConsumptionbyApplication:2016VS2021VS2027 1.4.2RetailPharmacies 1.4.3Hospitals 1.4.4Others 1.5StudyObjectives 1.6YearsConsidered 2GlobalMarketPerspective 2.1GlobalAntivenomRevenue(2016-2027) 2.1.1GlobalAntivenomRevenue(2016-2027) 2.1.2GlobalAntivenomSales(2016-2027) 2.2AntivenomMarketSizeacrossKeyGeographiesWorldwide:2016VS2021VS2027 2.2.1GlobalAntivenomSalesbyRegions(2016-2021) 2.2.2GlobalAntivenomRevenuebyRegions(2016-2021) 2.3GlobalTopAntivenomRegions(Countries)RankingbyMarketSize 2.4AntivenomIndustryTrends 2.4.1AntivenomMarketTopTrends 2.4.2MarketDrivers 2.4.3AntivenomMarketChallenges 2.4.4PortersFiveForcesAnalysis 2.4.5PrimaryInterviewswithKeyAntivenomPlayers:ViewsforFuture 3CompetitiveLandscapebyManufacturers 3.1GlobalTopAntivenomManufacturersbySales(2016-2021) 3.1.1GlobalAntivenomSalesbyManufacturers(2016-2021) 3.1.2GlobalAntivenomSalesMarketSharebyManufacturers(2016-2021) 3.1.3Global5and10LargestManufacturersbyAntivenomSalesin2020 3.2GlobalTopManufacturersAntivenombyRevenue 3.2.1GlobalAntivenomRevenuebyManufacturers(2016-2021) 3.2.2GlobalAntivenomRevenueSharebyManufacturers(2016-2021) 3.2.3GlobalAntivenomMarketConcentrationRatio(CR5andHHI) 3.3GlobalTopManufacturersbyCompanyType(Tier1,Tier2andTier3)(basedontheRevenueinAntivenomasof2020) 3.4GlobalAntivenomAverageSellingPrice(ASP)byManufacturers 3.5KeyManufacturersAntivenomPlants/FactoriesDistributionandAreaServed 3.6DateofKeyManufacturersEnterintoAntivenomMarket 3.7KeyManufacturersAntivenomProductOffered 3.8Mergers&Acquisitions,ExpansionPlans 4MarketSizebyType 4.1GlobalAntivenomHistoricMarketReviewbyType(2016-2021) 4.1.2GlobalAntivenomSalesMarketSharebyType(2016-2021) 4.1.3GlobalAntivenomRevenueMarketSharebyType(2016-2021) 4.1.4AntivenomPricebyType(2016-2021) 4.1GlobalAntivenomMarketEstimatesandForecastsbyType(2021-2027) 4.2.2GlobalAntivenomSalesForecastbyType(2021-2027) 4.2.3GlobalAntivenomRevenueForecastbyType(2021-2027) 4.2.4AntivenomPriceForecastbyType(2021-2027) 5GlobalAntivenomMarketSizebyApplication 5.1GlobalAntivenomHistoricMarketReviewbyApplication(2016-2021) 5.1.2GlobalAntivenomSalesMarketSharebyApplication(2016-2021) 5.1.3GlobalAntivenomRevenueMarketSharebyApplication(2016-2021) 5.1.4AntivenomPricebyApplication(2016-2021) 5.2GlobalAntivenomMarketEstimatesandForecastsbyApplication(2021-2027) 5.2.2GlobalAntivenomSalesForecastbyApplication(2021-2027) 5.2.3GlobalAntivenomRevenueForecastbyApplication(2021-2027) 5.2.4AntivenomPriceForecastbyApplication(2021-2027) 6NorthAmerica 6.1NorthAmericaAntivenomBreakdownDatabyCompany 6.2NorthAmericaAntivenomBreakdownDatabyType 6.3NorthAmericaAntivenomBreakdownDatabyApplication 6.4NorthAmericaAntivenomBreakdownDatabyCountries 6.4.1NorthAmericaAntivenomSalesbyCountries 6.4.2NorthAmericaAntivenomRevenuebyCountries 6.4.3U.S. 6.4.4Canada 7Europe 7.1EuropeAntivenomBreakdownDatabyCompany 7.2EuropeAntivenomBreakdownDatabyType 7.3EuropeAntivenomBreakdownDatabyApplication 7.4EuropeAntivenomBreakdownDatabyCountries 7.4.1EuropeAntivenomSalesbyCountries 7.4.2EuropeAntivenomRevenuebyCountries 7.4.3Germany 7.4.4France 7.4.5U.K. 7.4.6Italy 7.4.7Russia 8AsiaPacific 8.1AsiaPacificAntivenomBreakdownDatabyCompany 8.2AsiaPacificAntivenomBreakdownDatabyType 8.3AsiaPacificAntivenomBreakdownDatabyApplication 8.4AsiaPacificAntivenomBreakdownDatabyRegions 8.4.1AsiaPacificAntivenomSalesbyRegions 8.4.2AsiaPacificAntivenomRevenuebyRegions 8.4.3China 8.4.4Japan 8.4.5SouthKorea 8.4.6India 8.4.7Australia 8.4.8Taiwan 8.4.9Indonesia 8.4.10Thailand 8.4.11Malaysia 8.4.12Philippines 8.4.13Vietnam 9LatinAmerica 9.1LatinAmericaAntivenomBreakdownDatabyCompany 9.2LatinAmericaAntivenomBreakdownDatabyType 9.3LatinAmericaAntivenomBreakdownDatabyApplication 9.4LatinAmericaAntivenomBreakdownDatabyCountries 9.4.1LatinAmericaAntivenomSalesbyCountries 9.4.2LatinAmericaAntivenomRevenuebyCountries 9.4.3Mexico 9.4.4Brazil 9.4.5Argentina 10MiddleEastandAfrica 10.1MiddleEastandAfricaAntivenomBreakdownDatabyType 10.2MiddleEastandAfricaAntivenomBreakdownDatabyApplication 10.3MiddleEastandAfricaAntivenomBreakdownDatabyCountries 10.3.1MiddleEastandAfricaAntivenomSalesbyCountries 10.3.2MiddleEastandAfricaAntivenomRevenuebyCountries 10.3.3Turkey 10.3.4SaudiArabia 10.3.5U.A.E 11CompanyProfiles 11.1CSLBehring 11.1.1CSLBehringCorporationInformation 11.1.2CSLBehringBusinessOverviewandTotalRevenue(2020VS2018) 11.1.3CSLBehringAntivenomSales,Revenue,AverageSellingPrice(ASP)andGrossMargin(2016-2021) 11.1.4CSLBehringAntivenomProductsandServices 11.1.5CSLBehringSWOTAnalysis 11.1.6CSLBehringRecentDevelopments 11.2Merck&Co. 11.2.1Merck&Co.CorporationInformation 11.2.2Merck&Co.BusinessOverviewandTotalRevenue(2020VS2018) 11.2.3Merck&Co.AntivenomSales,Revenue,AverageSellingPrice(ASP)andGrossMargin(2016-2021) 11.2.4Merck&Co.AntivenomProductsandServices 11.2.5Merck&Co.SWOTAnalysis 11.2.6Merck&Co.RecentDevelopments 11.3BTGPlc 11.3.1BTGPlcCorporationInformation 11.3.2BTGPlcBusinessOverviewandTotalRevenue(2020VS2018) 11.3.3BTGPlcAntivenomSales,Revenue,AverageSellingPrice(ASP)andGrossMargin(2016-2021) 11.3.4BTGPlcAntivenomProductsandServices 11.3.5BTGPlcSWOTAnalysis 11.3.6BTGPlcRecentDevelopments 11.4Pfizer 11.4.1PfizerCorporationInformation 11.4.2PfizerBusinessOverviewandTotalRevenue(2020VS2018) 11.4.3PfizerAntivenomSales,Revenue,AverageSellingPrice(ASP)andGrossMargin(2016-2021) 11.4.4PfizerAntivenomProductsandServices 11.4.5PfizerSWOTAnalysis 11.4.6PfizerRecentDevelopments 11.5HaffkineBio-PharmaceuticalCorporation 11.5.1HaffkineBio-PharmaceuticalCorporationCorporationInformation 11.5.2HaffkineBio-PharmaceuticalCorporationBusinessOverviewandTotalRevenue(2020VS2018) 11.5.3HaffkineBio-PharmaceuticalCorporationAntivenomSales,Revenue,AverageSellingPrice(ASP)andGrossMargin(2016-2021) 11.5.4HaffkineBio-PharmaceuticalCorporationAntivenomProductsandServices 11.5.5HaffkineBio-PharmaceuticalCorporationSWOTAnalysis 11.5.6HaffkineBio-PharmaceuticalCorporationRecentDevelopments 11.6RareDiseaseTherapeutics 11.6.1RareDiseaseTherapeuticsCorporationInformation 11.6.2RareDiseaseTherapeuticsBusinessOverviewandTotalRevenue(2020VS2018) 11.6.3RareDiseaseTherapeuticsAntivenomSales,Revenue,AverageSellingPrice(ASP)andGrossMargin(2016-2021) 11.6.4RareDiseaseTherapeuticsAntivenomProductsandServices 11.6.5RareDiseaseTherapeuticsSWOTAnalysis 11.6.6RareDiseaseTherapeuticsRecentDevelopments 11.7FlynnPharma 11.7.1FlynnPharmaCorporationInformation 11.7.2FlynnPharmaBusinessOverviewandTotalRevenue(2020VS2018) 11.7.3FlynnPharmaAntivenomSales,Revenue,AverageSellingPrice(ASP)andGrossMargin(2016-2021) 11.7.4FlynnPharmaAntivenomProductsandServices 11.7.5FlynnPharmaSWOTAnalysis 11.7.6FlynnPharmaRecentDevelopments 11.8VinsBioproducts 11.8.1VinsBioproductsCorporationInformation 11.8.2VinsBioproductsBusinessOverviewandTotalRevenue(2020VS2018) 11.8.3VinsBioproductsAntivenomSales,Revenue,AverageSellingPrice(ASP)andGrossMargin(2016-2021) 11.8.4VinsBioproductsAntivenomProductsandServices 11.8.5VinsBioproductsSWOTAnalysis 11.8.6VinsBioproductsRecentDevelopments 11.9BharatSerumsandVaccines 11.9.1BharatSerumsandVaccinesCorporationInformation 11.9.2BharatSerumsandVaccinesBusinessOverviewandTotalRevenue(2020VS2018) 11.9.3BharatSerumsandVaccinesAntivenomSales,Revenue,AverageSellingPrice(ASP)andGrossMargin(2016-2021) 11.9.4BharatSerumsandVaccinesAntivenomProductsandServices 11.9.5BharatSerumsandVaccinesSWOTAnalysis 11.9.6BharatSerumsandVaccinesRecentDevelopments 11.10SerumBiotech 11.10.1SerumBiotechCorporationInformation 11.10.2SerumBiotechBusinessOverviewandTotalRevenue(2020VS2018) 11.10.3SerumBiotechAntivenomSales,Revenue,AverageSellingPrice(ASP)andGrossMargin(2016-2021) 11.10.4SerumBiotechAntivenomProductsandServices 11.10.5SerumBiotechSWOTAnalysis 11.10.6SerumBiotechRecentDevelopments 12SupplyChainandSalesChannelsAnalysis 12.1SupplyChainAnalysis 12.2SalesChannelsAnalysis 12.2.1AntivenomSalesChannels 12.2.2AntivenomDistributors 12.3AntivenomCustomers 13EstimatesandProjectionsbyRegions(2021-2027) 13.1GlobalAntivenomSalesForecast(2021-2027) 13.1.1GlobalAntivenomSalesForecastbyRegions(2021-2027) 13.1.2GlobalAntivenomRevenueForecastbyRegions(2021-2027) 13.2NorthAmericaMarketSizeForecast(2021-2027) 13.2.1NorthAmericaAntivenomSalesForecast(2021-2027) 13.2.2NorthAmericaAntivenomRevenueForecast(2021-2027) 13.2.3NorthAmericaAntivenomSizeForecastbyCounty(2021-2027) 13.3EuropeMarketSizeForecast(2021-2027) 13.3.1EuropeAntivenomSalesForecast(2021-2027) 13.3.2EuropeAntivenomRevenueForecast(2021-2027) 13.3.3EuropeAntivenomSizeForecastbyCounty(2021-2027) 13.4AsiaPacificMarketSizeForecast(2021-2027) 13.4.1AsiaPacificAntivenomSalesForecast(2021-2027) 13.4.2AsiaPacificAntivenomRevenueForecast(2021-2027) 13.4.3AsiaPacificAntivenomSizeForecastbyRegion(2021-2027) 13.5LatinAmericaMarketSizeForecast(2021-2027) 13.5.1LatinAmericaAntivenomSalesForecast(2021-2027) 13.5.2LatinAmericaAntivenomRevenueForecast(2021-2027) 13.5.3LatinAmericaAntivenomSizeForecastbyCounty(2021-2027) 13.6MiddleEastandAfricaMarketForecast 13.6.1MiddleEastandAfricaAntivenomSalesForecast(2021-2027) 13.6.2MiddleEastandAfricaAntivenomRevenueForecast(2021-2027) 13.6.3MiddleEastandAfricaAntivenomSizeForecastbyCounty(2021-2027) 14ResearchFindingsandConclusion 15Appendix 15.1ResearchMethodology 15.1.1Methodology/ResearchApproach 15.1.2DataSource 15.2AuthorDetails 15.3Disclaimer

List of Tables
Table 1. Antivenom Key Market Segments
Table 2. Ranking of Global Top Antivenom Manufacturers by Revenue (US$ Million) in 2020
Table 3. Global Antivenom Market Size Growth Rate by Type 2021-2027 (K Vials) & (Million US$)
Table 4. Major Manufacturers of Polyvalent antivenom
Table 5. Major Manufacturers of Monovalent antivenom
Table 6. Global Antivenom Market Share by Application 2020-2025 (K Vials)
Table 7. Global Antivenom Market Size by Regions 2016-2021 (K Vials) & (Million US$)
Table 8. Global Antivenom Sales by Regions 2016-2021 (K Vials)
Table 9. Global Antivenom Sales Market Share by Regions 2016-2021
Table 10. Global Antivenom Revenue by Regions 2016-2021 (Million US$)
Table 11. Global Antivenom Revenue Market Share by Regions 2016-2021
Table 12. Top Antivenom Regions (Countries) Ranking by Market Size (US$ Million) in 2020
Table 13. Market Top Trends
Table 14. Antivenom Key Drivers: Impact Analysis (2021-2027)
Table 15. Antivenom Key Challenges
Table 16. Main Points Interviewed from Key Antivenom Players: Views for Future
Table 17. Global Antivenom Sales by Manufacturers (2016-2021) (K Vials)
Table 18. Global Antivenom Sales Share by Manufacturers (2016-2021)
Table 19. Antivenom Revenue by Manufacturers (2016-2021) (Million US$)
Table 20. Antivenom Revenue Share by Manufacturers (2016-2021)
Table 21. Global Antivenom Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antivenom as of 2020)
Table 23. Key Manufacturers Antivenom Average Selling Price (ASP) (2016-2021) (USD/Vial)
Table 24. Key Manufacturers Antivenom Plants/Factories Distribution
Table 25. Key Manufacturers Antivenom Area Served
Table 26. Date of Key Manufacturers Enter into Antivenom Market
Table 27. Key Manufacturers Antivenom Product Type
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Polyvalent antivenom Sales and Revenue (2016-2021) (K Vials) & (Million US$)
Table 30. Global Monovalent antivenom Sales and Revenue (2016-2021) (K Vials) & (Million US$)
Table 31. Global Antivenom Sales (K Vials) by Type (2016-2021)
Table 32. Global Antivenom Sales Share by Type (2016-2021)
Table 33. Global Antivenom Revenue (US$ Million) Market Share by Type (2016-2021)
Table 34. Global Antivenom Price (K Vials) by Type (2016-2021)
Table 35. Global Antivenom Sales (K Vials) by Type (2021-2027)
Table 36. Global Antivenom Sales Share by Type (2021-2027)
Table 37. Global Antivenom Revenue (US$ Million) Market Share by Type (2021-2027)
Table 38. Global Antivenom Revenue Share by Type (2021-2027)
Table 39. Global Antivenom Price (K Vials) by Type (2021-2027)
Table 40. Global Antivenom Sales (K Vials) by Application (2016-2021)
Table 41. Global Antivenom Sales Share by Application (2016-2021)
Table 42. Global Antivenom Revenue (US$ Million) Market Share by Application (2016-2021)
Table 43. Global Antivenom Price by Application 2016-2021 (USD/Vial)
Table 44. Global Antivenom Sales by Application (2016-2021) (K Vials)
Table 45. Global Antivenom Sales Share by Application (2016-2021)
Table 46. Global Antivenom Revenue (US$ Million) Market Share by Application (2021-2027)
Table 47. Global Antivenom Revenue Share by Application (2021-2027)
Table 48. Global Antivenom Price (K Vials) by Application (2021-2027)
Table 49. North America Antivenom Sales by Company (2016-2021) (K Vials)
Table 50. North America Antivenom Sales Market Share by Company (2016-2021)
Table 51. North America Antivenom Sales by Type (2016-2021) (K Vials)
Table 52. North America Antivenom Sales Market Share by Type (2016-2021)
Table 53. North America Antivenom Sales by Application (2016-2021) (K Vials)
Table 54. North America Antivenom Sales Market Share by Application (2016-2021)
Table 55. North America Antivenom Sales by Countries (2016-2021) (K Vials)
Table 56. North America Antivenom Sales Market Share by Countries (2016-2021)
Table 57. North America Antivenom Revenue by Countries (2016-2021) (Million US$)
Table 58. North America Antivenom Revenue Market Share by Countries (2016-2021)
Table 59. Europe Antivenom Sales by Company (2016-2021) (K Vials)
Table 60. Europe Antivenom Sales Market Share by Company (2016-2021)
Table 61. Europe Antivenom Sales by Type (2016-2021) (K Vials)
Table 62. Europe Antivenom Sales Market Share by Type (2016-2021)
Table 63. Europe Antivenom Sales by Application (2016-2021) (K Vials)
Table 64. Europe Antivenom Sales Market Share by Application (2016-2021)
Table 65. Europe Antivenom Sales by Countries (2016-2021) (K Vials)
Table 66. Europe Antivenom Sales Market Share by Countries (2016-2021)
Table 67. Europe Antivenom Revenue by Countries (2016-2021) (Million US$)
Table 68. Europe Antivenom Revenue Market Share by Countries (2016-2021)
Table 69. Asia Pacific Antivenom Sales by Regions (2016-2021) (K Vials)
Table 70. Asia Pacific Antivenom Sales Market Share by Regions (2016-2021)
Table 71. Asia Pacific Antivenom Sales by Type (2016-2021) (K Vials)
Table 72. Asia Pacific Antivenom Sales Market Share by Type (2016-2021)
Table 73. Asia Pacific Antivenom Sales by Application (2016-2021) (K Vials)
Table 74. Asia Pacific Antivenom Sales Market Share by Application (2016-2021)
Table 75. Asia Pacific Antivenom Sales by Countries (2016-2021) (K Vials)
Table 76. Asia Pacific Antivenom Sales Market Share by Regions (2016-2021)
Table 77. Asia Pacific Antivenom Revenue by Regions (2016-2021) (Million US$)
Table 78. Asia Pacific Antivenom Revenue Market Share by Regions (2016-2021)
Table 79. Latin America Antivenom Sales by Company (2016-2021) (K Vials)
Table 80. Latin America Antivenom Sales Market Share by Company (2016-2021)
Table 81. Latin America Antivenom Sales by Type (2016-2021) (K Vials)
Table 82. Latin America Antivenom Sales Market Share by Type (2016-2021)
Table 83. Latin America Antivenom Sales by Application (2016-2021) (K Vials)
Table 84. Latin America Antivenom Sales Market Share by Application (2016-2021)
Table 85. Latin America Antivenom Sales by Countries (2016-2021) (K Vials)
Table 86. Latin America Antivenom Sales Market Share by Countries (2016-2021)
Table 87. Latin America Antivenom Revenue by Countries (2016-2021) (Million US$)
Table 88. Latin America Antivenom Revenue Market Share by Countries (2016-2021)
Table 89. Middle East and Africa Antivenom Sales by Type (2016-2021) (K Vials)
Table 90. Middle East and Africa Antivenom Sales Market Share by Type (2016-2021)
Table 91. Middle East and Africa Antivenom Sales by Application (2016-2021) (K Vials)
Table 92. Middle East and Africa Antivenom Sales Market Share by Application (2016-2021)
Table 93. Middle East and Africa Antivenom Sales by Countries (2016-2021) (K Vials)
Table 94. Middle East and Africa Antivenom Sales Market Share by Countries (2016-2021)
Table 95. Middle East and Africa Antivenom Revenue by Countries (2016-2021) (Million US$)
Table 96. Middle East and Africa Antivenom Revenue Market Share by Countries (2016-2021)
Table 97. CSL Behring Company Details
Table 98. CSL Behring Description and Business Overview
Table 99. CSL Behring Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 100. CSL Behring Antivenom Sales Growth Rate (2016-2021)
Table 101. CSL Behring Antivenom Sales Market Share in Global Market
Table 102. CSL Behring Recent Development
Table 103. Merck & Co. Company Details
Table 104. Merck & Co. Description and Business Overview
Table 105. Merck & Co. Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 106. Merck & Co. Antivenom Sales Growth Rate (2016-2021)
Table 107. Merck & Co. Antivenom Sales Market Share in Global Market
Table 108. Merck & Co. Recent Development
Table 109. BTG Plc Company Details
Table 110. BTG Plc Description and Business Overview
Table 111. BTG Plc Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 112. BTG Plc Antivenom Sales Growth Rate (2016-2021)
Table 113. BTG Plc Antivenom Sales Market Share in Global Market
Table 114. BTG Plc Recent Development
Table 115. Pfizer Company Details
Table 116. Pfizer Description and Business Overview
Table 117. Pfizer Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 118. Pfizer Antivenom Sales Growth Rate (2016-2021)
Table 119. Pfizer Antivenom Sales Market Share in Global Market
Table 120. Pfizer Recent Development
Table 121. Haffkine Bio-Pharmaceutical Corporation Company Details
Table 122. Haffkine Bio-Pharmaceutical Corporation Description and Business Overview
Table 123. Haffkine Bio-Pharmaceutical Corporation Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 124. Haffkine Bio-Pharmaceutical Corporation Antivenom Sales Growth Rate (2016-2021)
Table 125. Haffkine Bio-Pharmaceutical Corporation Antivenom Sales Market Share in Global Market
Table 126. Haffkine Bio-Pharmaceutical Corporation Recent Development
Table 127. Rare Disease Therapeutics Company Details
Table 128. Rare Disease Therapeutics Description and Business Overview
Table 129. Rare Disease Therapeutics Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 130. Rare Disease Therapeutics Antivenom Sales Growth Rate (2016-2021)
Table 131. Rare Disease Therapeutics Antivenom Sales Market Share in Global Market
Table 132. Rare Disease Therapeutics Recent Development
Table 133. Flynn Pharma Company Details
Table 134. Flynn Pharma Description and Business Overview
Table 135. Flynn Pharma Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 136. Flynn Pharma Antivenom Sales Growth Rate (2016-2021)
Table 137. Flynn Pharma Antivenom Sales Market Share in Global Market
Table 138. Flynn Pharma Recent Development
Table 139. Vins Bioproducts Company Details
Table 140. Vins Bioproducts Description and Business Overview
Table 141. Vins Bioproducts Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 142. Vins Bioproducts Antivenom Sales Growth Rate (2016-2021)
Table 143. Vins Bioproducts Antivenom Sales Market Share in Global Market
Table 144. Vins Bioproducts Recent Development
Table 145. Bharat Serums and Vaccines Company Details
Table 146. Bharat Serums and Vaccines Description and Business Overview
Table 147. Bharat Serums and Vaccines Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 148. Bharat Serums and Vaccines Antivenom Sales Growth Rate (2016-2021)
Table 149. Bharat Serums and Vaccines Antivenom Sales Market Share in Global Market
Table 150. Bharat Serums and Vaccines Recent Development
Table 151. Serum Biotech Company Details
Table 152. Serum Biotech Description and Business Overview
Table 153. Serum Biotech Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 154. Serum Biotech Antivenom Sales Growth Rate (2016-2021)
Table 155. Serum Biotech Antivenom Sales Market Share in Global Market
Table 156. Serum Biotech Recent Development
Table 157. Antivenom Distributors List
Table 158. Antivenom Customers List
Table 159. Global Antivenom Sales Forecast 2021-2027 (K Vials) & (Million US$)
Table 160. Global Antivenom Sales Forecast by Type 2021-2027 (K Vials)
Table 161. Global Antivenom Sales Forecast by Application 2021-2027 (K Vials)
Table 162. Global Antivenom Sales Forecast by Regions 2021-2027 (K Vials)
Table 163. Global Antivenom Revenue Forecast by Regions 2021-2027 (Million US$)
Table 164. North America Antivenom Sales Forecast by Countries 2021-2027 (K Vials)
Table 165. North America Antivenom Revenue Forecast by Countries 2021-2027
Table 166. Europe Antivenom Sales Forecast by Countries 2021-2027 (K Vials)
Table 167. Europe Antivenom Revenue Market Share Forecast by Countries 2021-2027
Table 168. Asia Pacific Antivenom Sales Forecast by Regions 2021-2027 (K Vials)
Table 169. Asia Pacific Antivenom Revenue Forecast by Regions 2021-2027 (Million US$)
Table 170. Latin America Antivenom Sales Forecast by Countries 2021-2027 (K Vials)
Table 171. Latin America Antivenom Revenue Forecast by Countries 2021-2027 (Million US$)
Table 172. Middle East and Africa Antivenom Sales Forecast by Regions 2021-2027 (K Vials)
Table 173. Middle East and Africa Antivenom Revenue Forecast by Regions 2021-2027 (Million US$)
Table 174. Research Programs/Design for This Report
Table 175. Key Data Information from Secondary Sources
Table 176. Key Data Information from Primary Sources
List of Figures
Figure 1. Antivenom Product Picture
Figure 2. Global Antivenom Sales Market Shar by Type 2016-2027
Figure 3. Polyvalent antivenom Figures
Figure 4. Monovalent antivenom Figures
Figure 5. Global Antivenom Sales Market Share by Application in 2020 & 2027
Figure 6. Retail Pharmacies Use Case
Figure 7. Hospitals Use Case
Figure 8. Others Use Case
Figure 9. Antivenom Report Years Considered
Figure 10. Global Antivenom Market Size 2016-2027 (Million US$)
Figure 11. Global Antivenom Sales 2016-2021 (K Vials)
Figure 12. Global Antivenom Market Size Market Share by Regions 2016-2021
Figure 13. Global Antivenom Sales Market Share by Regions in 2020
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Antivenom Sales Share by Manufacturers in 2020
Figure 16. The 5 and 10 Largest Manufacturers in the World: Market Share by Antivenom Sales in 2020
Figure 17. Antivenom Value Share by Manufacturers in 2020
Figure 18. Antivenom Revenue Share by Manufacturers In 2020
Figure 19. Antivenom Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 20. Global Antivenom Revenue Share by Type (2016-2021)
Figure 21. Global Antivenom Revenue Growth Rate by Type in 2016 & 2020
Figure 22. Global Antivenom Market Share by Price Range (2016-2021)
Figure 23. Global Antivenom Revenue Share by Application (2016-2021)
Figure 24. Global Antivenom Revenue Growth Rate by Application in 2016 & 2020
Figure 25. North America Antivenom Revenue Growth Rate 2016-2021 (Million US$)
Figure 26. U.S. Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 27. Canada Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 28. Europe Antivenom Revenue Growth Rate 2016-2021 (Million US$)
Figure 29. Germany Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 30. France Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 31. U.K. Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 32. Italy Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 33. Russia Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 34. Asia Pacific Antivenom Revenue Growth Rate 2016-2021 (Million US$)
Figure 35. China Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 36. Japan Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 37. South Korea Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 38. India Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 39. Australia Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 40. Taiwan Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 41. Indonesia Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 42. Thailand Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 43. Malaysia Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 44. Philippines Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 45. Vietnam Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 46. Latin America Antivenom Revenue Growth Rate 2016-2021 (Million US$)
Figure 47. Mexico Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 48. Brazil Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 49. Argentina Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 50. Middle East and Africa Antivenom Revenue Growth Rate 2016-2021 (Million US$)
Figure 51. Turkey Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 52. Saudi Arabia Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 53. U.A.E Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 54. CSL Behring Total Revenue (US$ Million): 2020 Compared with 2018
Figure 55. Merck & Co. Total Revenue (US$ Million): 2020 Compared with 2018
Figure 56. BTG Plc Total Revenue (US$ Million): 2020 Compared with 2018
Figure 57. Pfizer Total Revenue (US$ Million): 2020 Compared with 2018
Figure 58. Haffkine Bio-Pharmaceutical Corporation Total Revenue (US$ Million): 2020 Compared with 2018
Figure 59. Rare Disease Therapeutics Total Revenue (US$ Million): 2020 Compared with 2018
Figure 60. Flynn Pharma Total Revenue (US$ Million): 2020 Compared with 2018
Figure 61. Vins Bioproducts Total Revenue (US$ Million): 2020 Compared with 2018
Figure 62. Bharat Serums and Vaccines Total Revenue (US$ Million): 2020 Compared with 2018
Figure 63. Serum Biotech Total Revenue (US$ Million): 2020 Compared with 2018
Figure 64. Antivenom Value Chain
Figure 65. Channels of Distribution
Figure 66. Distributors Profiles
Figure 67. North America Antivenom Sales Growth Rate Forecast (2021-2027) (K Vials)
Figure 68. North America Antivenom Revenue Growth Rate Forecast (2021-2027) (US$ Million)
Figure 69. Europe Antivenom Sales Growth Rate Forecast (2021-2027) (K Vials)
Figure 70. Europe Antivenom Revenue Growth Rate Forecast (2021-2027) (US$ Million)
Figure 71. Asia Pacific Antivenom Sales Growth Rate Forecast (2021-2027) (K Vials)
Figure 72. Asia Pacific Antivenom Revenue Growth Rate Forecast (2021-2027) (US$ Million)
Figure 73. Latin America Antivenom Sales Growth Rate Forecast (2021-2027) (K Vials)
Figure 74. Latin America Antivenom Revenue Growth Rate Forecast (2021-2027) (US$ Million)
Figure 75. Middle East and Africa Antivenom Sales Growth Rate Forecast (2021-2027) (K Vials)
Figure 76. Middle East and Africa Antivenom Revenue Growth Rate Forecast (2021-2027) (US$ Million)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed

Antivenom Market Segments


Antivenom Product Type Outlook (Revenue, USD Million, 2021 2027)


  • Polyvalent antivenom
  • Monovalent antivenom

Antivenom Application Outlook (Revenue, USD Million, 2021 2027)


  • Retail Pharmacies
  • Hospitals
  • Others

Antivenom Regional Outlook (Revenue, USD Million, 2021 2027)


  • North America
    • Antivenom market, By Product Type Outlook
      • Polyvalent antivenom
      • Monovalent antivenom

    • Antivenom market, By Application Outlook
      • Retail Pharmacies
      • Hospitals
      • Others

  • Europe
    • Antivenom market, By Product Type Outlook
      • Polyvalent antivenom
      • Monovalent antivenom

    • Antivenom market, By Application Outlook
      • Retail Pharmacies
      • Hospitals
      • Others

  • Asia Pacific
    • Antivenom market, By Product Type Outlook
      • Polyvalent antivenom
      • Monovalent antivenom

    • Antivenom market, By Application Outlook
      • Retail Pharmacies
      • Hospitals
      • Others

  • Latin America
    • Antivenom market, By Product Type Outlook
      • Polyvalent antivenom
      • Monovalent antivenom

    • Antivenom market, By Application Outlook
      • Retail Pharmacies
      • Hospitals
      • Others

  • Middle East & Africa
    • Antivenom market, By Product Type Outlook
      • Polyvalent antivenom
      • Monovalent antivenom

    • Antivenom market, By Application Outlook
      • Retail Pharmacies
      • Hospitals
      • Others

Report Content:


Qualitative Analysis


  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Market size
  • Growth prospects
  • Porters analysis
  • PESTEL Analysis
  • Value Chain Analysis
  • Key market opportunities prioritized
  • Competitive landscape
    • Overview
    • Financials
    • Product benchmarking
    • Latest strategic developments

Quantitative Analysis


  • Market size, estimates, and forecasts from 2021 - 2027
  • Market revenue estimates for product type up to 2027
  • Market revenue estimates for application type up to 2027
  • Regional market size and forecast up to 2027
  • Company financials

Report Description


The Global Antivenom Market Report provides Insightful information to the clients enhancing their basic leadership capacity identified with the global Antivenom Market business, including market dynamics, segmentation, competition, and regional growth. The strategy of expansion has been adopted by key players who are increasing their production capacities to cater to the increasing demand for various application.

New traders at intervals the Antivenom Market face strong competition from ancient world traders as they try with technological revolutions, dependableness and commonplace of Antivenom Market product affairs. The report is at risk of project regarding this Antivenom Market evolutions and additionally the magnitude of competition, value and extra.

Leading market players: (Option 1: Free 25% Customization Profiles of 5 Additional Companies of your Choice)


This business intelligence report offers profiling of reputed companies that are operating in the market. Companies such as:

  • CSL Behring
  • Merck & Co.
  • BTG Plc
  • Pfizer
  • Haffkine Bio-Pharmaceutical Corporation
  • Rare Disease Therapeutics
  • Flynn Pharma
  • Vins Bioproducts
  • Bharat Serums and Vaccines
  • Serum Biotech

Others players have been profiled into detail so as to offer a glimpse of the market leaders. Moreover, parameters such as Antivenom related investment & spending and developments by major players of the market are tracked in this Global report.

Years considered for the study:


Antivenom Market

Antivenom Market

Report Highlights:


The Antivenom Market is widely partitioned reliant on the predictable updates in the enhancement of parameters for example, quality, trustworthiness, end customer solicitations, applications, and others. The Antivenom Market report contains general successful parameters, confinements, and besides has in detail illumination of the noteworthy data close by the present and future examples that may concern the advancement. The comprehensive Antivenom Market report elucidates within and outside representation of current advancements, parameters, and establishments.

The key regions analyzed in this study include North America, Europe, Japan, China, India, Korea, South East Asia, South America, Middle East and African countries. The leading players of Antivenom Market and their geographical presence across the globe are estimated based on production capacity, utilization ratio, consumer base, demand and supply scenario, profit margin and Antivenom marketers.

Data Lab Forecast performed primary as well as exhaustive secondary research for this study. We conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, DLF was able to include manufacturers that could not be identified due to the limitations of secondary research. We analysed product offerings, distribution channel and regional presence of all major companies in the industry.

Data Lab Forecast calculated the market size for the Antivenom market using a bottom-up approach, wherein manufacturers value data for different type (Polyvalent antivenom, Monovalent antivenom), of Antivenom market was recorded as well as forecast for the future years was made. Data Lab Forecast sourced these values from industry experts and company representatives, and externally validated through analyzing historical sales data of respective manufacturers to arrive at the overall market size. Various secondary sources such as company annual reports, white papers, investor presentations and financial reports were also studied by Data Lab Forecast.

Antivenom Market

Antivenom Market

Key Target Audience:


  • Antivenom market companies.
  • Research organizations and consulting companies.
  • Organizations, associations and alliances related to the Antivenom market industry.
  • Government bodies such as regulating authorities and policymakers.
  • Industry associations.

The study is useful in providing answers to several critical questions that are important for industry stakeholders, such as manufacturers, distributors, dealers and policymakers, about which market segments should be targeted over retail cosmetics outlets in coming years to strategize investments and capitalize on growth of the market.

Report Scope:


In this report, Antivenom market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

In terms of type, the Global Antivenom market is segregated into:


The report includes in-detail references of all the notable product categories as well as application specifications. The product segment is described on the basis of key player development traits, sales overview, volume based returns and the like.

  • Polyvalent antivenom
  • Monovalent antivenom

By end-user also classify into, the Global Antivenom market:


Global Antivenom market also specifically underpins end-use application scope and their improvements based on technological developments and consumer preferences.

  • Retail Pharmacies
  • Hospitals
  • Others

Highlights of this 2021-2027 Antivenom Market Report:

  • Market dynamics, Antivenom economy manufacturing, opportunities on the total pricing of this top manufacturer and improvement trend analysis;
  • Antivenom industry players at the general regional industry and economy synopsis;
  • Deep analysis of the most significant market players included by Worldwide Antivenom Market study report;
  • Understand more about the market plans that are increasingly now being adopted by leading Antivenom businesses;
  • Evaluation of this market character, namely market development drivers, essential challengers, inhibitors, and chances;
  • Strategically profile the key players and comprehensively analyze their growth strategies.

Competitive Landscape:

Company Profiles: Detailed analysis of the major companies presents in the Antivenom market.

Product Benchmarking: Benchmarking of most selling variant of all leading companies based on product type. In-depth analysis of benchmarking and recommendation on ideal product specifications.

Voice of Customer: Customer analysis by considering the major factors influencing the purchasing decision.

Available Customizations:

With the given market data, Data Lab Forecast offers customizations according to the companys specific needs. The following customization options are available for the report:

Channel Partner Analysis: Detailed list of distributors and dealers across the country.

Company Information: Detailed analysis and profiling of additional market players (up to five).

Product Information: Detailed analysis of new products in the market and their driving forces in the market.

In case you dont find what you are looking for, please get in touch with our custom research team at sales@datalabforecast.com
TableofContents 1ReportOverview 1.1ResearchScope 1.2TopAntivenomManufacturersCovered:RankingbyRevenue 1.3MarketSegmentbyType 1.3.1GlobalAntivenomMarketSizebyType:2016VS2021VS2027(US$Million) 1.3.2Polyvalentantivenom 1.3.3Monovalentantivenom 1.4MarketSegmentbyApplication 1.4.1GlobalAntivenomConsumptionbyApplication:2016VS2021VS2027 1.4.2RetailPharmacies 1.4.3Hospitals 1.4.4Others 1.5StudyObjectives 1.6YearsConsidered 2GlobalMarketPerspective 2.1GlobalAntivenomRevenue(2016-2027) 2.1.1GlobalAntivenomRevenue(2016-2027) 2.1.2GlobalAntivenomSales(2016-2027) 2.2AntivenomMarketSizeacrossKeyGeographiesWorldwide:2016VS2021VS2027 2.2.1GlobalAntivenomSalesbyRegions(2016-2021) 2.2.2GlobalAntivenomRevenuebyRegions(2016-2021) 2.3GlobalTopAntivenomRegions(Countries)RankingbyMarketSize 2.4AntivenomIndustryTrends 2.4.1AntivenomMarketTopTrends 2.4.2MarketDrivers 2.4.3AntivenomMarketChallenges 2.4.4PortersFiveForcesAnalysis 2.4.5PrimaryInterviewswithKeyAntivenomPlayers:ViewsforFuture 3CompetitiveLandscapebyManufacturers 3.1GlobalTopAntivenomManufacturersbySales(2016-2021) 3.1.1GlobalAntivenomSalesbyManufacturers(2016-2021) 3.1.2GlobalAntivenomSalesMarketSharebyManufacturers(2016-2021) 3.1.3Global5and10LargestManufacturersbyAntivenomSalesin2020 3.2GlobalTopManufacturersAntivenombyRevenue 3.2.1GlobalAntivenomRevenuebyManufacturers(2016-2021) 3.2.2GlobalAntivenomRevenueSharebyManufacturers(2016-2021) 3.2.3GlobalAntivenomMarketConcentrationRatio(CR5andHHI) 3.3GlobalTopManufacturersbyCompanyType(Tier1,Tier2andTier3)(basedontheRevenueinAntivenomasof2020) 3.4GlobalAntivenomAverageSellingPrice(ASP)byManufacturers 3.5KeyManufacturersAntivenomPlants/FactoriesDistributionandAreaServed 3.6DateofKeyManufacturersEnterintoAntivenomMarket 3.7KeyManufacturersAntivenomProductOffered 3.8Mergers&Acquisitions,ExpansionPlans 4MarketSizebyType 4.1GlobalAntivenomHistoricMarketReviewbyType(2016-2021) 4.1.2GlobalAntivenomSalesMarketSharebyType(2016-2021) 4.1.3GlobalAntivenomRevenueMarketSharebyType(2016-2021) 4.1.4AntivenomPricebyType(2016-2021) 4.1GlobalAntivenomMarketEstimatesandForecastsbyType(2021-2027) 4.2.2GlobalAntivenomSalesForecastbyType(2021-2027) 4.2.3GlobalAntivenomRevenueForecastbyType(2021-2027) 4.2.4AntivenomPriceForecastbyType(2021-2027) 5GlobalAntivenomMarketSizebyApplication 5.1GlobalAntivenomHistoricMarketReviewbyApplication(2016-2021) 5.1.2GlobalAntivenomSalesMarketSharebyApplication(2016-2021) 5.1.3GlobalAntivenomRevenueMarketSharebyApplication(2016-2021) 5.1.4AntivenomPricebyApplication(2016-2021) 5.2GlobalAntivenomMarketEstimatesandForecastsbyApplication(2021-2027) 5.2.2GlobalAntivenomSalesForecastbyApplication(2021-2027) 5.2.3GlobalAntivenomRevenueForecastbyApplication(2021-2027) 5.2.4AntivenomPriceForecastbyApplication(2021-2027) 6NorthAmerica 6.1NorthAmericaAntivenomBreakdownDatabyCompany 6.2NorthAmericaAntivenomBreakdownDatabyType 6.3NorthAmericaAntivenomBreakdownDatabyApplication 6.4NorthAmericaAntivenomBreakdownDatabyCountries 6.4.1NorthAmericaAntivenomSalesbyCountries 6.4.2NorthAmericaAntivenomRevenuebyCountries 6.4.3U.S. 6.4.4Canada 7Europe 7.1EuropeAntivenomBreakdownDatabyCompany 7.2EuropeAntivenomBreakdownDatabyType 7.3EuropeAntivenomBreakdownDatabyApplication 7.4EuropeAntivenomBreakdownDatabyCountries 7.4.1EuropeAntivenomSalesbyCountries 7.4.2EuropeAntivenomRevenuebyCountries 7.4.3Germany 7.4.4France 7.4.5U.K. 7.4.6Italy 7.4.7Russia 8AsiaPacific 8.1AsiaPacificAntivenomBreakdownDatabyCompany 8.2AsiaPacificAntivenomBreakdownDatabyType 8.3AsiaPacificAntivenomBreakdownDatabyApplication 8.4AsiaPacificAntivenomBreakdownDatabyRegions 8.4.1AsiaPacificAntivenomSalesbyRegions 8.4.2AsiaPacificAntivenomRevenuebyRegions 8.4.3China 8.4.4Japan 8.4.5SouthKorea 8.4.6India 8.4.7Australia 8.4.8Taiwan 8.4.9Indonesia 8.4.10Thailand 8.4.11Malaysia 8.4.12Philippines 8.4.13Vietnam 9LatinAmerica 9.1LatinAmericaAntivenomBreakdownDatabyCompany 9.2LatinAmericaAntivenomBreakdownDatabyType 9.3LatinAmericaAntivenomBreakdownDatabyApplication 9.4LatinAmericaAntivenomBreakdownDatabyCountries 9.4.1LatinAmericaAntivenomSalesbyCountries 9.4.2LatinAmericaAntivenomRevenuebyCountries 9.4.3Mexico 9.4.4Brazil 9.4.5Argentina 10MiddleEastandAfrica 10.1MiddleEastandAfricaAntivenomBreakdownDatabyType 10.2MiddleEastandAfricaAntivenomBreakdownDatabyApplication 10.3MiddleEastandAfricaAntivenomBreakdownDatabyCountries 10.3.1MiddleEastandAfricaAntivenomSalesbyCountries 10.3.2MiddleEastandAfricaAntivenomRevenuebyCountries 10.3.3Turkey 10.3.4SaudiArabia 10.3.5U.A.E 11CompanyProfiles 11.1CSLBehring 11.1.1CSLBehringCorporationInformation 11.1.2CSLBehringBusinessOverviewandTotalRevenue(2020VS2018) 11.1.3CSLBehringAntivenomSales,Revenue,AverageSellingPrice(ASP)andGrossMargin(2016-2021) 11.1.4CSLBehringAntivenomProductsandServices 11.1.5CSLBehringSWOTAnalysis 11.1.6CSLBehringRecentDevelopments 11.2Merck&Co. 11.2.1Merck&Co.CorporationInformation 11.2.2Merck&Co.BusinessOverviewandTotalRevenue(2020VS2018) 11.2.3Merck&Co.AntivenomSales,Revenue,AverageSellingPrice(ASP)andGrossMargin(2016-2021) 11.2.4Merck&Co.AntivenomProductsandServices 11.2.5Merck&Co.SWOTAnalysis 11.2.6Merck&Co.RecentDevelopments 11.3BTGPlc 11.3.1BTGPlcCorporationInformation 11.3.2BTGPlcBusinessOverviewandTotalRevenue(2020VS2018) 11.3.3BTGPlcAntivenomSales,Revenue,AverageSellingPrice(ASP)andGrossMargin(2016-2021) 11.3.4BTGPlcAntivenomProductsandServices 11.3.5BTGPlcSWOTAnalysis 11.3.6BTGPlcRecentDevelopments 11.4Pfizer 11.4.1PfizerCorporationInformation 11.4.2PfizerBusinessOverviewandTotalRevenue(2020VS2018) 11.4.3PfizerAntivenomSales,Revenue,AverageSellingPrice(ASP)andGrossMargin(2016-2021) 11.4.4PfizerAntivenomProductsandServices 11.4.5PfizerSWOTAnalysis 11.4.6PfizerRecentDevelopments 11.5HaffkineBio-PharmaceuticalCorporation 11.5.1HaffkineBio-PharmaceuticalCorporationCorporationInformation 11.5.2HaffkineBio-PharmaceuticalCorporationBusinessOverviewandTotalRevenue(2020VS2018) 11.5.3HaffkineBio-PharmaceuticalCorporationAntivenomSales,Revenue,AverageSellingPrice(ASP)andGrossMargin(2016-2021) 11.5.4HaffkineBio-PharmaceuticalCorporationAntivenomProductsandServices 11.5.5HaffkineBio-PharmaceuticalCorporationSWOTAnalysis 11.5.6HaffkineBio-PharmaceuticalCorporationRecentDevelopments 11.6RareDiseaseTherapeutics 11.6.1RareDiseaseTherapeuticsCorporationInformation 11.6.2RareDiseaseTherapeuticsBusinessOverviewandTotalRevenue(2020VS2018) 11.6.3RareDiseaseTherapeuticsAntivenomSales,Revenue,AverageSellingPrice(ASP)andGrossMargin(2016-2021) 11.6.4RareDiseaseTherapeuticsAntivenomProductsandServices 11.6.5RareDiseaseTherapeuticsSWOTAnalysis 11.6.6RareDiseaseTherapeuticsRecentDevelopments 11.7FlynnPharma 11.7.1FlynnPharmaCorporationInformation 11.7.2FlynnPharmaBusinessOverviewandTotalRevenue(2020VS2018) 11.7.3FlynnPharmaAntivenomSales,Revenue,AverageSellingPrice(ASP)andGrossMargin(2016-2021) 11.7.4FlynnPharmaAntivenomProductsandServices 11.7.5FlynnPharmaSWOTAnalysis 11.7.6FlynnPharmaRecentDevelopments 11.8VinsBioproducts 11.8.1VinsBioproductsCorporationInformation 11.8.2VinsBioproductsBusinessOverviewandTotalRevenue(2020VS2018) 11.8.3VinsBioproductsAntivenomSales,Revenue,AverageSellingPrice(ASP)andGrossMargin(2016-2021) 11.8.4VinsBioproductsAntivenomProductsandServices 11.8.5VinsBioproductsSWOTAnalysis 11.8.6VinsBioproductsRecentDevelopments 11.9BharatSerumsandVaccines 11.9.1BharatSerumsandVaccinesCorporationInformation 11.9.2BharatSerumsandVaccinesBusinessOverviewandTotalRevenue(2020VS2018) 11.9.3BharatSerumsandVaccinesAntivenomSales,Revenue,AverageSellingPrice(ASP)andGrossMargin(2016-2021) 11.9.4BharatSerumsandVaccinesAntivenomProductsandServices 11.9.5BharatSerumsandVaccinesSWOTAnalysis 11.9.6BharatSerumsandVaccinesRecentDevelopments 11.10SerumBiotech 11.10.1SerumBiotechCorporationInformation 11.10.2SerumBiotechBusinessOverviewandTotalRevenue(2020VS2018) 11.10.3SerumBiotechAntivenomSales,Revenue,AverageSellingPrice(ASP)andGrossMargin(2016-2021) 11.10.4SerumBiotechAntivenomProductsandServices 11.10.5SerumBiotechSWOTAnalysis 11.10.6SerumBiotechRecentDevelopments 12SupplyChainandSalesChannelsAnalysis 12.1SupplyChainAnalysis 12.2SalesChannelsAnalysis 12.2.1AntivenomSalesChannels 12.2.2AntivenomDistributors 12.3AntivenomCustomers 13EstimatesandProjectionsbyRegions(2021-2027) 13.1GlobalAntivenomSalesForecast(2021-2027) 13.1.1GlobalAntivenomSalesForecastbyRegions(2021-2027) 13.1.2GlobalAntivenomRevenueForecastbyRegions(2021-2027) 13.2NorthAmericaMarketSizeForecast(2021-2027) 13.2.1NorthAmericaAntivenomSalesForecast(2021-2027) 13.2.2NorthAmericaAntivenomRevenueForecast(2021-2027) 13.2.3NorthAmericaAntivenomSizeForecastbyCounty(2021-2027) 13.3EuropeMarketSizeForecast(2021-2027) 13.3.1EuropeAntivenomSalesForecast(2021-2027) 13.3.2EuropeAntivenomRevenueForecast(2021-2027) 13.3.3EuropeAntivenomSizeForecastbyCounty(2021-2027) 13.4AsiaPacificMarketSizeForecast(2021-2027) 13.4.1AsiaPacificAntivenomSalesForecast(2021-2027) 13.4.2AsiaPacificAntivenomRevenueForecast(2021-2027) 13.4.3AsiaPacificAntivenomSizeForecastbyRegion(2021-2027) 13.5LatinAmericaMarketSizeForecast(2021-2027) 13.5.1LatinAmericaAntivenomSalesForecast(2021-2027) 13.5.2LatinAmericaAntivenomRevenueForecast(2021-2027) 13.5.3LatinAmericaAntivenomSizeForecastbyCounty(2021-2027) 13.6MiddleEastandAfricaMarketForecast 13.6.1MiddleEastandAfricaAntivenomSalesForecast(2021-2027) 13.6.2MiddleEastandAfricaAntivenomRevenueForecast(2021-2027) 13.6.3MiddleEastandAfricaAntivenomSizeForecastbyCounty(2021-2027) 14ResearchFindingsandConclusion 15Appendix 15.1ResearchMethodology 15.1.1Methodology/ResearchApproach 15.1.2DataSource 15.2AuthorDetails 15.3Disclaimer

Antivenom Market Segments


Antivenom Product Type Outlook (Revenue, USD Million, 2021 2027)


  • Polyvalent antivenom
  • Monovalent antivenom

Antivenom Application Outlook (Revenue, USD Million, 2021 2027)


  • Retail Pharmacies
  • Hospitals
  • Others

Antivenom Regional Outlook (Revenue, USD Million, 2021 2027)


  • North America
    • Antivenom market, By Product Type Outlook
      • Polyvalent antivenom
      • Monovalent antivenom

    • Antivenom market, By Application Outlook
      • Retail Pharmacies
      • Hospitals
      • Others

  • Europe
    • Antivenom market, By Product Type Outlook
      • Polyvalent antivenom
      • Monovalent antivenom

    • Antivenom market, By Application Outlook
      • Retail Pharmacies
      • Hospitals
      • Others

  • Asia Pacific
    • Antivenom market, By Product Type Outlook
      • Polyvalent antivenom
      • Monovalent antivenom

    • Antivenom market, By Application Outlook
      • Retail Pharmacies
      • Hospitals
      • Others

  • Latin America
    • Antivenom market, By Product Type Outlook
      • Polyvalent antivenom
      • Monovalent antivenom

    • Antivenom market, By Application Outlook
      • Retail Pharmacies
      • Hospitals
      • Others

  • Middle East & Africa
    • Antivenom market, By Product Type Outlook
      • Polyvalent antivenom
      • Monovalent antivenom

    • Antivenom market, By Application Outlook
      • Retail Pharmacies
      • Hospitals
      • Others

Report Content:


Qualitative Analysis


  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Market size
  • Growth prospects
  • Porters analysis
  • PESTEL Analysis
  • Value Chain Analysis
  • Key market opportunities prioritized
  • Competitive landscape
    • Overview
    • Financials
    • Product benchmarking
    • Latest strategic developments

Quantitative Analysis


  • Market size, estimates, and forecasts from 2021 - 2027
  • Market revenue estimates for product type up to 2027
  • Market revenue estimates for application type up to 2027
  • Regional market size and forecast up to 2027
  • Company financials
List of Tables
Table 1. Antivenom Key Market Segments
Table 2. Ranking of Global Top Antivenom Manufacturers by Revenue (US$ Million) in 2020
Table 3. Global Antivenom Market Size Growth Rate by Type 2021-2027 (K Vials) & (Million US$)
Table 4. Major Manufacturers of Polyvalent antivenom
Table 5. Major Manufacturers of Monovalent antivenom
Table 6. Global Antivenom Market Share by Application 2020-2025 (K Vials)
Table 7. Global Antivenom Market Size by Regions 2016-2021 (K Vials) & (Million US$)
Table 8. Global Antivenom Sales by Regions 2016-2021 (K Vials)
Table 9. Global Antivenom Sales Market Share by Regions 2016-2021
Table 10. Global Antivenom Revenue by Regions 2016-2021 (Million US$)
Table 11. Global Antivenom Revenue Market Share by Regions 2016-2021
Table 12. Top Antivenom Regions (Countries) Ranking by Market Size (US$ Million) in 2020
Table 13. Market Top Trends
Table 14. Antivenom Key Drivers: Impact Analysis (2021-2027)
Table 15. Antivenom Key Challenges
Table 16. Main Points Interviewed from Key Antivenom Players: Views for Future
Table 17. Global Antivenom Sales by Manufacturers (2016-2021) (K Vials)
Table 18. Global Antivenom Sales Share by Manufacturers (2016-2021)
Table 19. Antivenom Revenue by Manufacturers (2016-2021) (Million US$)
Table 20. Antivenom Revenue Share by Manufacturers (2016-2021)
Table 21. Global Antivenom Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antivenom as of 2020)
Table 23. Key Manufacturers Antivenom Average Selling Price (ASP) (2016-2021) (USD/Vial)
Table 24. Key Manufacturers Antivenom Plants/Factories Distribution
Table 25. Key Manufacturers Antivenom Area Served
Table 26. Date of Key Manufacturers Enter into Antivenom Market
Table 27. Key Manufacturers Antivenom Product Type
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Polyvalent antivenom Sales and Revenue (2016-2021) (K Vials) & (Million US$)
Table 30. Global Monovalent antivenom Sales and Revenue (2016-2021) (K Vials) & (Million US$)
Table 31. Global Antivenom Sales (K Vials) by Type (2016-2021)
Table 32. Global Antivenom Sales Share by Type (2016-2021)
Table 33. Global Antivenom Revenue (US$ Million) Market Share by Type (2016-2021)
Table 34. Global Antivenom Price (K Vials) by Type (2016-2021)
Table 35. Global Antivenom Sales (K Vials) by Type (2021-2027)
Table 36. Global Antivenom Sales Share by Type (2021-2027)
Table 37. Global Antivenom Revenue (US$ Million) Market Share by Type (2021-2027)
Table 38. Global Antivenom Revenue Share by Type (2021-2027)
Table 39. Global Antivenom Price (K Vials) by Type (2021-2027)
Table 40. Global Antivenom Sales (K Vials) by Application (2016-2021)
Table 41. Global Antivenom Sales Share by Application (2016-2021)
Table 42. Global Antivenom Revenue (US$ Million) Market Share by Application (2016-2021)
Table 43. Global Antivenom Price by Application 2016-2021 (USD/Vial)
Table 44. Global Antivenom Sales by Application (2016-2021) (K Vials)
Table 45. Global Antivenom Sales Share by Application (2016-2021)
Table 46. Global Antivenom Revenue (US$ Million) Market Share by Application (2021-2027)
Table 47. Global Antivenom Revenue Share by Application (2021-2027)
Table 48. Global Antivenom Price (K Vials) by Application (2021-2027)
Table 49. North America Antivenom Sales by Company (2016-2021) (K Vials)
Table 50. North America Antivenom Sales Market Share by Company (2016-2021)
Table 51. North America Antivenom Sales by Type (2016-2021) (K Vials)
Table 52. North America Antivenom Sales Market Share by Type (2016-2021)
Table 53. North America Antivenom Sales by Application (2016-2021) (K Vials)
Table 54. North America Antivenom Sales Market Share by Application (2016-2021)
Table 55. North America Antivenom Sales by Countries (2016-2021) (K Vials)
Table 56. North America Antivenom Sales Market Share by Countries (2016-2021)
Table 57. North America Antivenom Revenue by Countries (2016-2021) (Million US$)
Table 58. North America Antivenom Revenue Market Share by Countries (2016-2021)
Table 59. Europe Antivenom Sales by Company (2016-2021) (K Vials)
Table 60. Europe Antivenom Sales Market Share by Company (2016-2021)
Table 61. Europe Antivenom Sales by Type (2016-2021) (K Vials)
Table 62. Europe Antivenom Sales Market Share by Type (2016-2021)
Table 63. Europe Antivenom Sales by Application (2016-2021) (K Vials)
Table 64. Europe Antivenom Sales Market Share by Application (2016-2021)
Table 65. Europe Antivenom Sales by Countries (2016-2021) (K Vials)
Table 66. Europe Antivenom Sales Market Share by Countries (2016-2021)
Table 67. Europe Antivenom Revenue by Countries (2016-2021) (Million US$)
Table 68. Europe Antivenom Revenue Market Share by Countries (2016-2021)
Table 69. Asia Pacific Antivenom Sales by Regions (2016-2021) (K Vials)
Table 70. Asia Pacific Antivenom Sales Market Share by Regions (2016-2021)
Table 71. Asia Pacific Antivenom Sales by Type (2016-2021) (K Vials)
Table 72. Asia Pacific Antivenom Sales Market Share by Type (2016-2021)
Table 73. Asia Pacific Antivenom Sales by Application (2016-2021) (K Vials)
Table 74. Asia Pacific Antivenom Sales Market Share by Application (2016-2021)
Table 75. Asia Pacific Antivenom Sales by Countries (2016-2021) (K Vials)
Table 76. Asia Pacific Antivenom Sales Market Share by Regions (2016-2021)
Table 77. Asia Pacific Antivenom Revenue by Regions (2016-2021) (Million US$)
Table 78. Asia Pacific Antivenom Revenue Market Share by Regions (2016-2021)
Table 79. Latin America Antivenom Sales by Company (2016-2021) (K Vials)
Table 80. Latin America Antivenom Sales Market Share by Company (2016-2021)
Table 81. Latin America Antivenom Sales by Type (2016-2021) (K Vials)
Table 82. Latin America Antivenom Sales Market Share by Type (2016-2021)
Table 83. Latin America Antivenom Sales by Application (2016-2021) (K Vials)
Table 84. Latin America Antivenom Sales Market Share by Application (2016-2021)
Table 85. Latin America Antivenom Sales by Countries (2016-2021) (K Vials)
Table 86. Latin America Antivenom Sales Market Share by Countries (2016-2021)
Table 87. Latin America Antivenom Revenue by Countries (2016-2021) (Million US$)
Table 88. Latin America Antivenom Revenue Market Share by Countries (2016-2021)
Table 89. Middle East and Africa Antivenom Sales by Type (2016-2021) (K Vials)
Table 90. Middle East and Africa Antivenom Sales Market Share by Type (2016-2021)
Table 91. Middle East and Africa Antivenom Sales by Application (2016-2021) (K Vials)
Table 92. Middle East and Africa Antivenom Sales Market Share by Application (2016-2021)
Table 93. Middle East and Africa Antivenom Sales by Countries (2016-2021) (K Vials)
Table 94. Middle East and Africa Antivenom Sales Market Share by Countries (2016-2021)
Table 95. Middle East and Africa Antivenom Revenue by Countries (2016-2021) (Million US$)
Table 96. Middle East and Africa Antivenom Revenue Market Share by Countries (2016-2021)
Table 97. CSL Behring Company Details
Table 98. CSL Behring Description and Business Overview
Table 99. CSL Behring Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 100. CSL Behring Antivenom Sales Growth Rate (2016-2021)
Table 101. CSL Behring Antivenom Sales Market Share in Global Market
Table 102. CSL Behring Recent Development
Table 103. Merck & Co. Company Details
Table 104. Merck & Co. Description and Business Overview
Table 105. Merck & Co. Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 106. Merck & Co. Antivenom Sales Growth Rate (2016-2021)
Table 107. Merck & Co. Antivenom Sales Market Share in Global Market
Table 108. Merck & Co. Recent Development
Table 109. BTG Plc Company Details
Table 110. BTG Plc Description and Business Overview
Table 111. BTG Plc Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 112. BTG Plc Antivenom Sales Growth Rate (2016-2021)
Table 113. BTG Plc Antivenom Sales Market Share in Global Market
Table 114. BTG Plc Recent Development
Table 115. Pfizer Company Details
Table 116. Pfizer Description and Business Overview
Table 117. Pfizer Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 118. Pfizer Antivenom Sales Growth Rate (2016-2021)
Table 119. Pfizer Antivenom Sales Market Share in Global Market
Table 120. Pfizer Recent Development
Table 121. Haffkine Bio-Pharmaceutical Corporation Company Details
Table 122. Haffkine Bio-Pharmaceutical Corporation Description and Business Overview
Table 123. Haffkine Bio-Pharmaceutical Corporation Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 124. Haffkine Bio-Pharmaceutical Corporation Antivenom Sales Growth Rate (2016-2021)
Table 125. Haffkine Bio-Pharmaceutical Corporation Antivenom Sales Market Share in Global Market
Table 126. Haffkine Bio-Pharmaceutical Corporation Recent Development
Table 127. Rare Disease Therapeutics Company Details
Table 128. Rare Disease Therapeutics Description and Business Overview
Table 129. Rare Disease Therapeutics Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 130. Rare Disease Therapeutics Antivenom Sales Growth Rate (2016-2021)
Table 131. Rare Disease Therapeutics Antivenom Sales Market Share in Global Market
Table 132. Rare Disease Therapeutics Recent Development
Table 133. Flynn Pharma Company Details
Table 134. Flynn Pharma Description and Business Overview
Table 135. Flynn Pharma Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 136. Flynn Pharma Antivenom Sales Growth Rate (2016-2021)
Table 137. Flynn Pharma Antivenom Sales Market Share in Global Market
Table 138. Flynn Pharma Recent Development
Table 139. Vins Bioproducts Company Details
Table 140. Vins Bioproducts Description and Business Overview
Table 141. Vins Bioproducts Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 142. Vins Bioproducts Antivenom Sales Growth Rate (2016-2021)
Table 143. Vins Bioproducts Antivenom Sales Market Share in Global Market
Table 144. Vins Bioproducts Recent Development
Table 145. Bharat Serums and Vaccines Company Details
Table 146. Bharat Serums and Vaccines Description and Business Overview
Table 147. Bharat Serums and Vaccines Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 148. Bharat Serums and Vaccines Antivenom Sales Growth Rate (2016-2021)
Table 149. Bharat Serums and Vaccines Antivenom Sales Market Share in Global Market
Table 150. Bharat Serums and Vaccines Recent Development
Table 151. Serum Biotech Company Details
Table 152. Serum Biotech Description and Business Overview
Table 153. Serum Biotech Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 154. Serum Biotech Antivenom Sales Growth Rate (2016-2021)
Table 155. Serum Biotech Antivenom Sales Market Share in Global Market
Table 156. Serum Biotech Recent Development
Table 157. Antivenom Distributors List
Table 158. Antivenom Customers List
Table 159. Global Antivenom Sales Forecast 2021-2027 (K Vials) & (Million US$)
Table 160. Global Antivenom Sales Forecast by Type 2021-2027 (K Vials)
Table 161. Global Antivenom Sales Forecast by Application 2021-2027 (K Vials)
Table 162. Global Antivenom Sales Forecast by Regions 2021-2027 (K Vials)
Table 163. Global Antivenom Revenue Forecast by Regions 2021-2027 (Million US$)
Table 164. North America Antivenom Sales Forecast by Countries 2021-2027 (K Vials)
Table 165. North America Antivenom Revenue Forecast by Countries 2021-2027
Table 166. Europe Antivenom Sales Forecast by Countries 2021-2027 (K Vials)
Table 167. Europe Antivenom Revenue Market Share Forecast by Countries 2021-2027
Table 168. Asia Pacific Antivenom Sales Forecast by Regions 2021-2027 (K Vials)
Table 169. Asia Pacific Antivenom Revenue Forecast by Regions 2021-2027 (Million US$)
Table 170. Latin America Antivenom Sales Forecast by Countries 2021-2027 (K Vials)
Table 171. Latin America Antivenom Revenue Forecast by Countries 2021-2027 (Million US$)
Table 172. Middle East and Africa Antivenom Sales Forecast by Regions 2021-2027 (K Vials)
Table 173. Middle East and Africa Antivenom Revenue Forecast by Regions 2021-2027 (Million US$)
Table 174. Research Programs/Design for This Report
Table 175. Key Data Information from Secondary Sources
Table 176. Key Data Information from Primary Sources
List of Figures
Figure 1. Antivenom Product Picture
Figure 2. Global Antivenom Sales Market Shar by Type 2016-2027
Figure 3. Polyvalent antivenom Figures
Figure 4. Monovalent antivenom Figures
Figure 5. Global Antivenom Sales Market Share by Application in 2020 & 2027
Figure 6. Retail Pharmacies Use Case
Figure 7. Hospitals Use Case
Figure 8. Others Use Case
Figure 9. Antivenom Report Years Considered
Figure 10. Global Antivenom Market Size 2016-2027 (Million US$)
Figure 11. Global Antivenom Sales 2016-2021 (K Vials)
Figure 12. Global Antivenom Market Size Market Share by Regions 2016-2021
Figure 13. Global Antivenom Sales Market Share by Regions in 2020
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Antivenom Sales Share by Manufacturers in 2020
Figure 16. The 5 and 10 Largest Manufacturers in the World: Market Share by Antivenom Sales in 2020
Figure 17. Antivenom Value Share by Manufacturers in 2020
Figure 18. Antivenom Revenue Share by Manufacturers In 2020
Figure 19. Antivenom Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 20. Global Antivenom Revenue Share by Type (2016-2021)
Figure 21. Global Antivenom Revenue Growth Rate by Type in 2016 & 2020
Figure 22. Global Antivenom Market Share by Price Range (2016-2021)
Figure 23. Global Antivenom Revenue Share by Application (2016-2021)
Figure 24. Global Antivenom Revenue Growth Rate by Application in 2016 & 2020
Figure 25. North America Antivenom Revenue Growth Rate 2016-2021 (Million US$)
Figure 26. U.S. Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 27. Canada Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 28. Europe Antivenom Revenue Growth Rate 2016-2021 (Million US$)
Figure 29. Germany Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 30. France Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 31. U.K. Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 32. Italy Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 33. Russia Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 34. Asia Pacific Antivenom Revenue Growth Rate 2016-2021 (Million US$)
Figure 35. China Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 36. Japan Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 37. South Korea Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 38. India Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 39. Australia Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 40. Taiwan Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 41. Indonesia Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 42. Thailand Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 43. Malaysia Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 44. Philippines Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 45. Vietnam Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 46. Latin America Antivenom Revenue Growth Rate 2016-2021 (Million US$)
Figure 47. Mexico Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 48. Brazil Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 49. Argentina Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 50. Middle East and Africa Antivenom Revenue Growth Rate 2016-2021 (Million US$)
Figure 51. Turkey Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 52. Saudi Arabia Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 53. U.A.E Antivenom Sales Growth Rate (2016-2021) (K Vials)
Figure 54. CSL Behring Total Revenue (US$ Million): 2020 Compared with 2018
Figure 55. Merck & Co. Total Revenue (US$ Million): 2020 Compared with 2018
Figure 56. BTG Plc Total Revenue (US$ Million): 2020 Compared with 2018
Figure 57. Pfizer Total Revenue (US$ Million): 2020 Compared with 2018
Figure 58. Haffkine Bio-Pharmaceutical Corporation Total Revenue (US$ Million): 2020 Compared with 2018
Figure 59. Rare Disease Therapeutics Total Revenue (US$ Million): 2020 Compared with 2018
Figure 60. Flynn Pharma Total Revenue (US$ Million): 2020 Compared with 2018
Figure 61. Vins Bioproducts Total Revenue (US$ Million): 2020 Compared with 2018
Figure 62. Bharat Serums and Vaccines Total Revenue (US$ Million): 2020 Compared with 2018
Figure 63. Serum Biotech Total Revenue (US$ Million): 2020 Compared with 2018
Figure 64. Antivenom Value Chain
Figure 65. Channels of Distribution
Figure 66. Distributors Profiles
Figure 67. North America Antivenom Sales Growth Rate Forecast (2021-2027) (K Vials)
Figure 68. North America Antivenom Revenue Growth Rate Forecast (2021-2027) (US$ Million)
Figure 69. Europe Antivenom Sales Growth Rate Forecast (2021-2027) (K Vials)
Figure 70. Europe Antivenom Revenue Growth Rate Forecast (2021-2027) (US$ Million)
Figure 71. Asia Pacific Antivenom Sales Growth Rate Forecast (2021-2027) (K Vials)
Figure 72. Asia Pacific Antivenom Revenue Growth Rate Forecast (2021-2027) (US$ Million)
Figure 73. Latin America Antivenom Sales Growth Rate Forecast (2021-2027) (K Vials)
Figure 74. Latin America Antivenom Revenue Growth Rate Forecast (2021-2027) (US$ Million)
Figure 75. Middle East and Africa Antivenom Sales Growth Rate Forecast (2021-2027) (K Vials)
Figure 76. Middle East and Africa Antivenom Revenue Growth Rate Forecast (2021-2027) (US$ Million)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed
Choose License Type
  • $4250  
  • $6250  
  • $8250  

Secure Payment


img1

Related Reports

Antibody Drug Conjugates Contract Manufacturing Market

Report Description According to the new market study, we provide a comprehensive and in-depth analys

Read More

Therapeutic Drug Monitoring Market

Report Description According to the new market study, we provide a comprehensive and in-depth analys

Read More

Topical Drug Delivery System Market

Report Description According to the new market study, we provide a comprehensive and in-depth analys

Read More